At least 5 members of the D series of resolvins (RvDs) viz., RvD1, AT-RVD1, RvD3, AT-RvD3, and RvD5, activate their target cells through this receptor; these results have led to naming GPR32 the RVD1 receptor (see Resolvin#Mechanisms of Action). RvDs are members of the specialized proresolving mediators (SPM) class of polyunsaturated fatty acid metabolites. RVDs are metabolites of the omega-3 fatty acid, docosahexaenoic acid (DHA), and, along with other SRMs contribute to the inhibition and resolution of a diverse range of inflammation and inflammation-related responses as well as to the healing of these inflammatory lesions in animals and humans. The metabolism of DHA to RVD's and the activation of GPR32 by these RVD's are proposed to be one mechanism by which omega-3 fatty acids may ameliorate inflammation as well as various inflammation-based and other diseases.
^Marchese A, Nguyen T, Malik P, Xu S, Cheng R, Xie Z, Heng HH, George SR, Kolakowski LF, O'Dowd BF (June 1998). "Cloning genes encoding receptors related to chemoattractant receptors". Genomics. 50 (2): 281–6. doi:10.1006/geno.1998.5297. PMID9653656.
^ abSchmid M, Gemperle C, Rimann N, Hersberger M (2016). "Resolvin D1 Polarizes Primary Human Macrophages toward a Proresolution Phenotype through GPR32". Journal of Immunology (Baltimore, Md. : 1950). 196 (8): 3429–37. doi:10.4049/jimmunol.1501701. PMID26969756.
^Serhan CN, Chiang N, Dalli J, Levy BD (February 2015). "Lipid mediators in the resolution of inflammation". Cold Spring Harbor Perspectives in Biology. 7 (2): a016311. doi:10.1101/cshperspect.a016311. PMID25359497.